Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Pelthos Therapeutics ( (PTHS) ) has shared an update.
On November 6, 2025, Pelthos Therapeutics acquired the U.S. commercialization rights to Xepi, a topical treatment for impetigo, from Biofrontera and Ferrer. This acquisition adds a complementary product to Pelthos’ portfolio, aimed at addressing antimicrobial resistance in pediatric dermatology. Concurrently, Pelthos closed an $18 million private convertible notes financing with investors, including Ligand Pharmaceuticals, to support the acquisition, relaunch Xepi, and accelerate the commercialization of ZELSUVMI. The financing reflects investor confidence and is expected to strengthen Pelthos’ balance sheet and support its commercial growth.
The most recent analyst rating on (PTHS) stock is a Buy with a $50.00 price target. To see the full list of analyst forecasts on Pelthos Therapeutics stock, see the PTHS Stock Forecast page.
More about Pelthos Therapeutics
Pelthos Therapeutics is a biopharmaceutical company focused on commercializing innovative therapeutic products to address unmet patient needs. Its lead product, ZELSUVMI, is a topical gel approved for the treatment of molluscum contagiosum.
Average Trading Volume: 12,491
Technical Sentiment Signal: Strong Buy
Current Market Cap: $113.5M
Learn more about PTHS stock on TipRanks’ Stock Analysis page.